{"id":"NCT00143390","sponsor":"Pfizer","briefTitle":"Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer","officialTitle":"A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) Vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-04","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2005-09-02","resultsPosted":"2012-01-25","lastUpdate":"2012-01-25"},"enrollment":298,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"exemestane","otherNames":[]},{"type":"DRUG","name":"anastrozole","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.","primaryOutcome":{"measure":"Time to Progression (TTP) - Expert Evaluation Committee Assessment","timeFrame":"Up to 2008 days of the treatment","effectByArm":[{"arm":"Exemestane","deltaMin":13.8,"sd":null},{"arm":"Anastrozole","deltaMin":11.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":47,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":149},"commonTop":["Nasopharyngitis","Arthralgia","Hot flush","Back pain","Nausea"]}}